Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Buthionine sulfoximine||BSO||Buthionine sulfoximine (BSO) is a GSH synthesis inhibitor, which results in increased reactive oxygen species, thereby possibly leading to apoptotic and/or cytotoxic activity (PMID: 17991446, PMID: 27092812).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ARID1A dec exp||ovarian cancer||predicted - sensitive||Buthionine sulfoximine||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).||30686770|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|